Technology
Health
Biotechnology

OpGen

$0.4475
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.0221 (5.26%) Today
+$0.0054 (1.22%) After Hours

Why Robinhood?

You can buy or sell OpGen and other stocks, options, ETFs, and crypto commission-free!

About

OpGen, Inc. engages in the development of molecular information products and services for global healthcare settings. It helps to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). Read More The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.

Employees
50
Headquarters
Gaithersburg, Maryland
Founded
2001
Market Cap
3.82M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
199.44K
High Today
$0.448
Low Today
$0.41
Open Price
$0.43
Volume
59.30K
52 Week High
$2.90
52 Week Low
$0.36

Collections

Technology
Health
Biotechnology
Healthcare
2015 IPO
US
North America

News

Seeking AlphaMay 14

OpGen, Inc. CEO Evan Jones on Q1 2019 Results - Earnings Call Transcript

OpGen, Inc. (NASDAQ:OPGN) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Evan Jones - Chairman and Chief Executive Officer Timothy Dec - Chief Financial Officer Conference Call Participants Edward Marks - H.C. Wainwright & Co. Nathan Weinstein - Aegis Capital Corporation Maxim Jacobs - Edison Group Benjamin Haynor - Alliance Global Partners Anthony Polak - Aegis Capital Corp. John Power - Redwood MicroCap Fund Inc. Operator Welcome to the OpGen First Quarter 2019 C...

70
Seeking AlphaMay 14

OpGen up 10% premarket on U.S. application for molecular test

Thinly traded nano cap OpGen (NASDAQ:OPGN) is up 10% premarket on light volume on the heels of its 501(k) submission to the FDA seeking clearance for its Acuitas AMR Gene Panel test for the detection of antimicrobial resistance genes in bacterial isolates.

94
Yahoo FinanceMay 7

Will OpGen, Inc. (OPGN) Report Negative Q1 Earnings? What You Should Know

The market expects OpGen, Inc. (OPGN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2019. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they...

144

Earnings

-$1.38
-$0.94
-$0.51
-$0.07
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.31 per share
Actual
-$0.36 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.